期刊
BIOMATERIALS
卷 63, 期 -, 页码 168-176出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2015.06.013
关键词
Tumor cells; SELEX; Aptamer; Heterogeneous nuclear ribonucleoprotein; A2/B1; Nanoparticles
资金
- Chinese National High-Tech Research and Development Program [2012AA022501]
- National Natural Science Foundation of China [21175152, 81001262]
- National Science and Technology Major Project of the Ministry of Science and Technology of China [2012ZX09301003-001-010]
- Beijing Municipal National Science Foundation [7132159]
In this study, we further investigated a previously developed aptamer targeting ROS 17/2.8 (rat osteosarcoma) cells. We found that this C6-8 aptamer specifically binds to heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 and that it specifically labeled multiple tumor-cell lines as effectively as hnRNP A2/B1 monoclonal antibodies. When conjugated with fluorescent carbon nanodots (CDots) it could freely enter multiple living tumor cell lines (HepG2, MCF-7, H1299, and HeLa), whose growth it inhibited by targeting hnRNP A2/B1. Similar inhibitory effects were observed when the GFP-HepG2 hepatocarcinoma cells treated with C6-8-conjugated CDots were implanted in nude mice. Our work provides a new aptamer for targeting/labeling multiple tumor cell types, and its nanoparticle conjugates bring further advantages that increase its potential for use in cancer diagnosis and therapy. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据